Consun Pharmaceutical Group Limited (“Consun Pharma”) released its Monthly Return for the period ended 31 July 2026, confirming stable capital structure and full compliance with Hong Kong listing requirements.

Authorised Share Capital • Authorised shares remain at 5.00 billion ordinary shares with a par value of HKD 0.10, representing authorised share capital of HKD 500.00 million. No increase or decrease was recorded during the month.

Issued and Treasury Shares • Issued shares (excluding treasury shares) stood at 839.05 million. • Treasury shares totalled 2.50 million, leaving the overall issued share count unchanged at 841.55 million. • The company reported zero movements in either issued or treasury shares for July; consequently, no funds were raised.

Public Float Compliance • Consun Pharma confirmed that the public float exceeded the Main Board’s Initial Prescribed Threshold of 25% as at 31 July 2026.

Share Option Schemes • 2013 Share Option Scheme: 7.07 million options remained outstanding, with no exercises or cancellations during the month. • 2024 Share Option Scheme: No options were outstanding yet, while capacity allows up to 84.28 million shares to be granted in the future.

Other Securities • The issuer reported no outstanding warrants, convertibles, or other arrangements to issue shares.

Governance Confirmation • The filing, signed by Company Secretary Gao Haien on 4 August 2026, confirms that all regulatory, listing-rule and statutory obligations related to the company’s securities have been met.